Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256508 | 0.99 | DRD2 (0.38) | DRD2DRD4DRD3MAOAPNMT | |
| SCHEMBL5252579 | 0.83 | PNMT (0.49) | DRD2DRD4DRD3MAOAPNMT | |
| SCHEMBL5254175 | 0.81 | DRD2 (0.42) | DRD2DRD4DRD3MAOAPNMT | |
| SCHEMBL7018897 | 0.81 | DRD2 (0.38) | DRD2DRD4DRD3MAOAPNMT | |
| SCHEMBL5256511 | 0.80 | DRD2 (0.38) | DRD2DRD4DRD3MAOAPNMT | |
| SCHEMBL7189694 | 0.79 | DRD3 (0.51) | DRD2DRD4DRD3MAOAPNMT | |
| SCHEMBL2416249 | 0.77 | LIPG (0.44) | DRD2DRD4DRD3PNMT | |
| SCHEMBL8662797 | 0.76 | DRD2 (0.43) | DRD2DRD4DRD3MAOAPNMT | |
| SCHEMBL28975089 | 0.76 | LIPG (0.46) | DRD2DRD4DRD3 | |
| SCHEMBL29508750 | 0.76 | LIPG (0.46) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100384825-C | Benzheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 2008-04-30 | — | — | CN | disclosed |
| US-6642223-B2 | A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-0765314-B1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMA CO LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| CN-1104418-C | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 2003-04-02 | — | — | CN | disclosed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| CN-1313280-A | Benzheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 2001-09-19 | — | — | CN | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| CN-1150799-A | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-05-28 | — | — | CN | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | DRD2 211/4885DRD4 296/4885DRD3 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.